-Reuters
Inhibrx Announces Preliminary Data From The Phase 1 Trial Of Inbrx-109 For The Treatment Of Ewing Sarcoma
Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1